News | Cardiac Diagnostics | October 04, 2021

FDA Clears Nanowear Platform to Implement AI-based Home Diagnostics and Monitoring Network

System uses a wearable cloth-based nanosensor technology to monitor patients for worsening heart failure, post-surgical care and hypertension

SimpleSense is an FDA cleared remote diagnostic platform. The cloth-based nanosensor technology undergarment monitors multiple patient vitals such as heart rate, blood pressure, respiration rate, and physical activity.
SimpleSense is an FDA cleared remote diagnostic platform. The cloth-based nanosensor technology undergarment monitors multiple patient vitals such as heart rate, blood pressure, respiration rate, and physical activity.

October 4, 2021 – Nanowear, a hospital-at-home and remote diagnostic platform that used  proprietary wearable cloth nanotechnology sensors and artificial intelligence (AI), received its third FDA 510(k) clearance and first software-only clearance as an end-to-end digital platform. This clearance enables Nanowear to implement standalone AI and deep learning algorithms that will inform remote diagnoses as software-as-a-medical sevice (SaMD). 

The company is also working on FDA clearances for its software to diagnose or monitor hypertension, COPD, sleep apnea, worsening heart failure and post-surgical recovery.

Nanowear’s SimpleSense uses its proprietary cloth-based, wearable smart nanosensor technology to capture and analyze these low-noise, and 85 hospital-grade biomarkers using time-synchronous scattering methods. 

“AI has the invaluable ability to assist healthcare providers and payers in tracking complex biological systems and individual risk patterns within the human body where the data is inherently high-dimensional,” said Peter Norvig, director of research at Google and co-author of a popular university textbook in artificial intelligence, "Artificial Intelligence: A Modern Approach. “When time-synchronously tracking a complex system like a patient’s heart, lungs and upper vascular system, the data captured needs to match the system’s level of complexity. Nanowear’s 85+ biomarkers of high-fidelity data within a closed loop system enables unique AI and deep learning algorithms to ensure that need is met.”

“The largest bottleneck for any AI deployment is data preparation, which can take 70% - 80% of the time in any given application,” said Venk Varadan, co-founder and CEO of Nanowear. “Unlike wrist or armband device-enabled hospital-at-home platforms that do not yield high-fidelity longitudinal data, our SimpleSense platform utilizes clinical-grade biomarkers with a high SNR (signal-to-noise) ratio. The time required to see results with our neural network is significantly shorter, meaning we have the profound ability to scale the capabilities of our platform immediately. SimpleSense truly does get smarter with each patient.”

This FDA 510(k) clearance establishes Nanowear’s core data assets, secures existing data architecture, and unifies the digital platform through guiding principles like security, privacy, modularity, scalability, interoperability and utility. This unified digital platform integrates hospital-grade nanosensors, telehealth software and AI-driven decision support to radically transform virtual care and enable providers to triage risk profiles of the cardio, pulmonary and upper vascular systems of patients while they are in the comfort of their own home.

For more information: www.nanowearinc.com  

Find more wearable cardiac monitoring technologies

Related Content

News | Heart Failure

October 1, 2021 — A pooled analysis of two randomized trials has demonstrated the beneficial effects of empagliflozin in ...

Home October 04, 2021
Home
News | Heart Failure

September 28, 2021 — Hemodynamic guided management using the CardioMEMS device may reduce heart failure hospitalizations ...

Home September 28, 2021
Home
News | Heart Failure

September 22, 2021 — A cardiothoracic surgical team with University of Louisville Health – Jewish Hospital has performed ...

Home September 22, 2021
Home
News | Heart Failure

September 21, 2021 — The European Society of Cardiology (ESC) Guidelines for the diagnosis and treatment of acute and ...

Home September 21, 2021
Home
News | Heart Failure

June 15, 2021 — VoluMetrix, a Nashville-based biotech startup dedicated to creating a new wave of solutions for vital ...

Home June 15, 2021
Home
News | Heart Failure

June 7, 2021 – Cardiologists at Henry Ford Hospital are first in the U.S. and second in the world to implant a ...

Home June 07, 2021
Home
News | Heart Failure

May 19, 2021 — Among patients with both heart failure and atrial fibrillation (AFib), treatment strategies focused on ...

Home May 19, 2021
Home
News | Heart Failure

May 18, 2021 — The experimental heart failure drug omecamtiv mecarbil reduced heart failure hospitalizations by a ...

Home May 18, 2021
Home
News | Heart Failure

May 15, 2021 — The combination heart failure drug sacubitril/valsartan (Entresto) did not significantly reduce the rate ...

Home May 15, 2021
Home
News | Heart Failure

May 11, 2021 — Patients hospitalized with COVID-19 may be at risk of developing heart failure even if they do not have a ...

Home May 11, 2021
Home
Subscribe Now